- Exchange: NASDAQ GS
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Therapeutics
AVANIR Pharmaceuticals Inc
Add to PortfolioAVNR:US
2.8400 USD 0.0200 0.71%As of 20:10:00 ET on 05/25/2012.
Snapshot for AVANIR Pharmaceuticals Inc (AVNR)
| Open: | 2.8100 | Day's Range: | 2.8100 - 2.8700 | Volume: | 494,275 | Bid: | 2.8300 |
|---|---|---|---|---|---|---|---|
| Previous Close: | 2.8200 | 52wk Range: | 1.7700 - 4.7400 | 1-Yr Rtn: | -39.19% | Ask: | 2.8400 |
Key Statistics for AVNR
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E (09/2012) | - |
| Earnings Per Share (USD) (ttm) | -0.5200 |
| Est. EPS (USD) (09/2012) | -0.4140 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 385.35 |
| Shares Outstanding (M) | 135.68 |
| Enterprise Value (M USD) (ttm) | 318.64 |
| Enterprise Value/EBITDA (ttm) | - |
| Price/Book (mrq) | 6.4915 |
| Price/Sale (ttm) | 14.9763 |
| Dividend Indicated Gross Yield | 0.0000 |
| Next Earnings Announcement | 08/08/2012 |
More AVNR Key Statistics
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Financials for AVNR
- Operating
- Investing
- Financing (M/USD)
Company Profile & Key Executives for AVNR
AVANIR Pharmaceuticals Inc. develops, acquires, and markets treatments for central nervous system disorders, inflammation, and infectious diseases. The Company develops treatments for pseudobulbar affect, diabetic peripheral neuropathic pain, and other conditions. AVANIR out-licensed its moniclonal antibodies, and produces an over-the-counter treatment for cold sores.
| Craig A WheelerChairman | Keith A KatkinPresident/CEO |
| Randall E KayeSenior VP/Chief Medical Ofcr | Gregory J Flesher "Greg"Senior VP/Chief Business Officer |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Links
Top Forex Trading Resources
Advertisement
Advertisement
Advertisements
Rate this Page